SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 2 — Focused Visit (Follow-up) — Emily Dickinson — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.

PatientEmily Dickinson
Date of birth1830-12-10
IdentifiersMRN HR-NI023-SYN-TD; SSN (made up) 000-23-6081
Document date1885-02-02
AuthorLucinda Hartwell, MD
CustodianSt. Posthumous Health Center

Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.

Chief Complaint

Three-week kidney and blood pressure review; nephrology consultation and kidney ultrasound on the same trip. [S]

History of Present Illness

Ms. Dickinson comes to the clinic for the first time in two years, on a quiet early appointment that combines this review, a kidney ultrasound, and her nephrology consultation so that she makes one trip. She started losartan 50 mg, atorvastatin 20 mg, and vitamin D3 three weeks ago and stopped naproxen. Her headaches are less frequent, about twice a week, and she takes acetaminophen for them. The morning nausea has eased. She has had no lightheadedness, cough, or muscle aches. Her home blood pressure averages 150/90 on her own upper-arm cuff, which read within 4 mmHg of the clinic device today. She has cut down on salted foods. She saw Dr. Adeyemi of nephrology this morning after the ultrasound. [S]

ElementDetail
HeadachesAbout twice a week, down from most days; acetaminophen helps; no naproxen
Medication toleranceNo lightheadedness, cough, or muscle aches
Home blood pressureAverage 150/90 mmHg; her cuff agrees with the clinic device
DietLess salted and processed food
AccessOne combined clinic trip for review, ultrasound, and nephrology

Review of Systems

SystemResultFinding
NeurologicalPositiveHeadaches about twice a week, milder; no visual change or weakness
GastrointestinalNegativeMorning nausea eased; no vomiting
CardiovascularNegativeNo chest pain, palpitations, or ankle swelling
MusculoskeletalNegativeNo muscle aches on atorvastatin
GenitourinaryNegativeNo blood in the urine, frothy urine, or urinary symptoms

5 systems reviewed. [S]

Medications

MedicationFrequencyRouteDatesStatusEvidence
Naproxen sodium 220 mg oral tablet, two tablets by mouth as needed for headache (over the counter)Two tablets as needed, up to twice a dayOral route1884-10-01 to 1885-01-12stoppedS
Losartan 50 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route1885-01-12 to 1885-02-02completedS
Losartan 100 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route1885-02-02activeS
Atorvastatin 20 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route1885-01-12activeS
Cholecalciferol (vitamin D3) 25 mcg (1,000 units) oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route1885-01-12activeS
Acetaminophen 500 mg oral tablet, two tablets by mouth every 6 hours as needed for headache, no more than 3 g a dayTwo tablets every 6 hours as needed; maximum 6 tablets a dayOral route1885-01-12activeS
Dapagliflozin 10 mg oral tablet, one tablet by mouth dailyOne tablet by mouth dailyOral route1885-02-02activeS

Allergies and Intolerances

AllergyReactionStatusEvidence
No known allergyactiveS

Vital Signs

DateMeasureValueUnitProvenance
1885-02-02Body height163cmS
1885-02-02Body weight53.8kgS
1885-02-02Body mass index (BMI) [Ratio]20.2kg/m2S
1885-02-02Systolic blood pressure148mm[Hg]S
1885-02-02Diastolic blood pressure88mm[Hg]S
1885-02-02Heart rate74/minS
1885-02-02Respiratory rate14/minS
1885-02-02Body temperature36.5CelS
1885-02-02Oxygen saturation in Arterial blood by Pulse oximetry98%S

Results

DateMeasureValueUnitReference rangeFlagProvenance
1885-02-02Sodium [Moles/volume] in Serum or Plasma140mmol/L135-145 mmol/LNormalS
1885-02-02Potassium [Moles/volume] in Serum or Plasma4.6mmol/L3.5-5.1 mmol/LNormalS
1885-02-02Carbon dioxide, total [Moles/volume] in Serum or Plasma24mmol/L22-29 mmol/LNormalS
1885-02-02Urea nitrogen [Mass/volume] in Serum or Plasma22mg/dL6-21 mg/dLHighS
1885-02-02Creatinine [Mass/volume] in Serum or Plasma1.26mg/dL0.59-1.04 mg/dLHighS
1885-02-02Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 1880)/1.73 sq M51mL/min/{1.73_m2}>=60 mL/min/1.73 m²LowS
1885-02-02Glucose [Mass/volume] in Serum or Plasma90mg/dL70-99 mg/dLNormalS
1885-02-02Albumin/Creatinine [Mass Ratio] in Urine262mg/g<=30 mg/gHighS

Physical Exam

Vital signs recorded on 1885-02-02; see the Vital Signs section. [S]

SystemFinding
GeneralSlight, composed, and a little tired after the trip; asked to wait in a quiet side room rather than the waiting area
CardiovascularRegular rhythm; no murmur; no edema
AbdomenSoft; no renal bruit
Mental statusAlert and precise; mood "better"; reactive affect

Problems

ProblemClinical statusVerificationCodeProvenance
Chronic kidney disease stage G3a A2, attributed to hypertension; synthetic modern diagnosis linked to the Bright's disease entered on her death certificateactiveconfirmed N18.31S — Synthetic modern diagnosis. Bright's disease as her recorded cause of death is documented (D); what it meant in her case is a retrospective question (R), and no kidney test from her lifetime exists.
Hypertension with chronic kidney disease (hypertensive chronic kidney disease, stage 3a); synthetic modern diagnosis linked to the retrospective view that she had severe hypertensionactiveconfirmed I12.9S — Synthetic modern diagnosis; severe hypertension is a retrospective interpretation (R, possible), and no blood pressure from her lifetime exists.
Vitamin D deficiency with a mildly raised PTH in chronic kidney diseaseactiveconfirmed E55.9S — Synthetic laboratory finding at the intake visit.

Assessment and Plan

Protocol monitoring: items the monitoring protocol calls for at this visit. [S]

DomainMeasureIntervalStatusDetail
LaboratoryPotassium and creatinine after starting an ARB2 to 4 weeks after starting or increasing an ACE inhibitor, ARB, SGLT2 inhibitor, or MRACompleted todayPotassium 4.6 mmol/L, creatinine 1.26 mg/dL, eGFR 51, three weeks after starting losartan
LaboratoryUrine albumin-creatinine ratio, confirmatoryRepeat to confirm albuminuria at diagnosis; then with each eGFR drawCompleted today262 mg/g, confirming A2 (240 mg/g at intake)
ImagingKidney ultrasoundAt diagnosis when the cause is uncertain; no routine surveillance imagingCompleted todayNormal-sized kidneys, mildly echogenic; no obstruction, stones, or cysts
ReferralNephrology consultationAt diagnosis of albuminuric chronic kidney disease in a younger adult; or when KFRE or eGFR thresholds are metCompleted todaySeen today; agrees with hypertensive kidney disease and advises dapagliflozin and a maximum-dose ARB
ExaminationStandardized office and home blood pressureEvery visitCompleted today148/88 mmHg in the clinic after five minutes' rest, average of two readings; home average 150/90
ExaminationWeight and cardiac auscultationEvery visitCompleted today53.8 kg; regular rhythm, no murmur
Medication safetyMedication review: NSAID avoidance and dose adjustmentEvery visitCompleted todayNo naproxen since intake; acetaminophen twice a week; doses suit eGFR 51
Medication safetyStatin toleranceAt each review after startingCompleted todayNo muscle aches on atorvastatin 20 mg
LaboratoryCalcium, phosphate, PTH, and 25-hydroxyvitamin DBaseline at G3a, then every 6 to 12 monthsUp to dateBaseline at intake: PTH 74 pg/mL and vitamin D 21 ng/mL; on vitamin D3; recheck at six to twelve months
LaboratoryHemoglobinAt least yearly in G3Up to date12.3 g/dL at intake
SurveyKFRE 2- and 5-year riskYearly in G3 to G5Up to date0.5 and 1.6 percent at intake, below referral thresholds
SurveyPHQ-9Yearly with hypertension; repeat if symptoms changeUp to date6 at intake, mostly from tiredness and poor sleep with headaches
Self-managementSodium, home blood pressure, and sick-day rulesEvery visitCompleted todayLess salted food; weekly home readings; sick-day rules explained verbally

Goal progress:

Guideline basis: KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (2024); KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease (2021); 2017 ACC/AHA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults (2017); CMID: Clinical Monitoring Intelligence Database, chronic kidney disease, hypertension, and depression monographs (2026)

Follow-up: Video visit in four weeks with home vital signs and home blood tests for potassium and creatinine. Next scheduled visit 1885-03-02: video visit four weeks after the losartan increase and dapagliflozin start, with home vital signs and home blood tests. [S]